SLE patients took disease-modifying agents (steroids [n = 25], mycophenolate [n = 17], hydroxychloroquine [n = 11], and warfarin [n = 12]), whereas both patient groups took renin-angiotensin system blockers (SLE: n = 14, 52%; CAD: n = 25, 100%), calcium-channel blockers (SLE: n = 5, 19%; CAD: n = 18, 72%), statins (SLE: n = 3, 11%; CAD: n = 25, 100%), and aspirin (SLE: n = 6, 22%; CAD: n = 25, 100%). This evidence concerns the gene REN and systemic lupus erythematosus.